Finoriq research workspace
Arcturus Therapeutics Holdings Inc. (ARCT) SEC Filings & Filing Highlights
Arcturus Therapeutics Holdings Inc. also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic. Review ARCT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
- Company
- Arcturus Therapeutics Holdings Inc. (ARCT)
- Ticker
- ARCT
- Market Cap
- $170.8M
- Latest Price
- $6.01
- Industry
- Biotech & Pharma
Arcturus Therapeutics Holdings Inc. (ARCT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Arcturus Therapeutics Holdings Inc. (ARCT).
| Event | Form | Date |
|---|---|---|
| Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advanc...Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis | 8-K7.01 | 2026-07-02 |
| Master Services AgreementOn June 26, 2026, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware co... | 8-K1.01 | 2026-07-02 |
| To approve, on a non-binding advisory basis, the resolution approving named executive officer c...On June 5, 2026, Arcturus Therapeutics Holdings Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Meeting”).The total... | 8-K5.07 | 2026-06-05 |
| Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline ProgressArcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress | 8-K7.01 | 2026-05-07 |
| Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company....Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company. Mr. Mulroy will become the Company’s princi... | 8-K5.02 | 2026-05-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.